Estamos no ar no ! Saiba mais

Amedisys

AMED

Valor de mercado US$ 3,32 bi

Deslistada

AMED foi retirado da bolsa em 14 de agosto de 2025.

Voltar ao ranking

Sobre: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Funcionários: 19.000

Saúde Estabelecimentos de assistência médica

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 0%

Neutro 0%

Negativo 0%

Twilio Set to Join S&P MidCap 400

NEW YORK , Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE: TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE: UNH) acquired Amedisys in a deal completed today.

Twilio Set to Join S&P MidCap 400

UnitedHealth to sell off 164 locations to settle US challenge to Amedisys deal

UnitedHealth Group has agreed to sell off 164 hospice and home health locations to resolve U.S. antitrust concerns over its $3.3 billion acquisition of Amedisys , the U.S. Justice Department said on Thursday.

UnitedHealth to sell off 164 locations to settle US challenge to Amedisys deal

Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors

AMED's planned merger with UnitedHealth remains on the rocks with regulatory overhang still an issue. The deal is also asymmetrically weighted in UNH's favor, with the latter up for no penalty if it fails. Not so for AMED. Aside from this, there are internal factors dragging on AMED's business performance.

Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors

Zacks Investment Research

Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?

The Motley Fool

Amedisys (AMED) Q2 Revenue Tops 5%

Amedisys (AMED) Q2 Revenue Tops 5%

Amedisys (AMED) Q2 Revenue Tops 5%

Zacks Investment Research

Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings

Zacks Investment Research

Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates

Amedisys (AMED) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to earnings of $1.32 per share a year ago.

Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates

Amedisys Reports Second Quarter 2025 Financial Results

BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.

Amedisys Reports Second Quarter 2025 Financial Results

Zacks Investment Research

Here's Why You Should Retain AMED Stock in Your Portfolio for Now

Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

Here's Why You Should Retain AMED Stock in Your Portfolio for Now

Zacks Investment Research

AMED or CHE: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?

AMED or CHE: Which Is the Better Value Stock Right Now?

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™